The Intervention in Myocarditis and Acute Cardiomyopathy-2 (IMAC-2) trial, which included 373 patients (38% women), found no significant difference in the use of angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors or beta-blockers between men and women (37). The gene discussed is ACE; the disease is myocarditis.